TCT 2019—KRD induction in multiple myeloma: An interview with David Chung, MD


  • Yael Waknine
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

David J. Chung, MD, PhD, Medical Oncologist at Memorial Sloan Kettering Cancer Center in NY, NY, was interviewed by Yael Waknine of Univadis at the TCT meeting held February 20-24, 2019, in Houston, TX.

  • Carfilzomib-lenalidomide-dexamethasone (KRD) has shown promising efficacy and may eventually supplant bortezomib-lenalidomide-dexamethasone (VRD) as the standard triplet induction regimen for patients with newly-diagnosed multiple myeloma undergoing autologous stem cell transplant.
  • Compared with VRD (n=126), KRD (n=101) yielded higher rates of very good partial response (VGPR) or better, including bone marrow minimal residual disease (MRD) negativity:
    • Complete response (CR)/MRD+: 17.8% vs 7.9%.
    • CR/MRD: 20.8% vs 15.9%.
    • VGPR/MRD+: 39.6% vs 34.9%.
    • VGPR/ MRD: 10.9% vs 6.3%.
  • KRD yielded lower viable CD34+ peripheral stem cell content (63.54 vs 111.31 cells/mcL; P=.0019), but similar total yield (9.44 vs 11.21 x 106; P=.17) and time to engraftment.
  • Autograft purity/MRD-negativity was higher with KRD (81.1% vs 59.4%), but sample size precluded statistical significance (P=.086).
  • Longer follow-up will be required to determine whether higher autograft MRD-negativity has a positive effect on rate and duration of post-transplant disease control, Dr. Chung noted.

Highlights from TCT Meetings 2019